Jeffrey Dierks Sells 1,123 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total value of $44,920.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07.
• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12.

Harmony Biosciences Trading Up 3.6 %

Shares of HRMY stock opened at $40.46 on Wednesday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a 50 day moving average price of $34.46 and a 200 day moving average price of $34.96. The stock has a market capitalization of $2.31 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 0.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Monday, January 13th. Mizuho increased their price target on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Cantor Fitzgerald boosted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research note on Thursday, January 16th. Finally, Raymond James reissued an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $55.00.

Hedge Funds Weigh In On Harmony Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after acquiring an additional 436 shares in the last quarter. Mendota Financial Group LLC increased its position in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. CWM LLC lifted its position in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after purchasing an additional 775 shares during the last quarter. Quarry LP purchased a new stake in shares of Harmony Biosciences during the 2nd quarter worth $62,000. Finally, Quantbot Technologies LP acquired a new position in shares of Harmony Biosciences during the third quarter worth $74,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.